	US 12,433,951 B2
	Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
Janet Yikai Jin, Foster City, CA (US); Philip B. Komarnitsky, Chestnut Hill, MA (US); Mirella Lazarov, Simi Valley, CA (US); and Anita Reddy, Pleasanton, CA (US)
Assigned to AbbVie Manufacturing Management Unlimited Company, Dublin (IE)
Filed by AbbVie Manufacturing Management Unlimited Company, Dublin (IE)
Filed on Apr. 6, 2022, as Appl. No. 17/714,724.
Claims priority of provisional application 63/171,571, filed on Apr. 6, 2021.
Claims priority of provisional application 63/171,536, filed on Apr. 6, 2021.
Prior Publication US 2022/0323597 A1, Oct. 13, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 31/517 (2006.01); A61K 45/06 (2006.01); A61K 47/68 (2017.01)

CPC A61K 47/68031 (2023.08) [A61K 31/517 (2013.01); A61K 45/06 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01)]

3 Claims

1. A method of treating non-squamous non-small cell lung cancer (“NSCLC”) tumors that express c-Met in a plurality of human subjects, comprising the steps of:

(a) determining or having determined whether the tumors exhibit c-Met high expression, wherein c-Met high expression is defined by ≥50% of the neoplastic cells from tumor tissue of the non-squamous NSCLC having 3+ membrane or membrane+cytoplasmic staining if assessed by the c-Met Teliso-V Staining Protocol;

(b) if the tumor tissue does not exhibit c-Met high expression, excluding the subject having the tumor that does not exhibit c-Met high expression from treatment;

(c) if the tumor tissue exhibits c-Met high expression, selecting the subject for treatment and intravenously administering 1.6 mg/kg or 1.9 mg/kg of telisotuzumab vedotin once every two weeks (Q2W) to the selected subject, wherein the non-squamous NSCLC tumor does not carry a mutated EGFR gene.